Autonomix Medical, Inc. (AMIX): Nasdaq/NYSE listing notice — Autonomix Medical receives Nasdaq bid price deficiency notice; 180-day cure period

Autonomix Medical, Inc.

Received Nasdaq letter on Jan 14, 2026: bid price below $1.00 for 30 consecutive business days.
Initial 180-day compliance period ends July 13, 2026; need $1.00 close for 10 consecutive days.
If non-compliant by July 13, may get second 180-day period if meets other listing standards.
Company may consider a reverse stock split to regain compliance with Bid Price Rule.
No guarantee of regaining compliance; delisting possible if not cured or appeal fails.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Autonomix Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Autonomix Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-001381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.